Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Maturi, Raj K., M.D., P.C. Clear all
Completed Phase 2 Interventional Results available

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

NCT02732899
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Sirolimus, EYLEA
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
50 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

NCT02357342
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus, Standard of Care intravitreal injections of anti-VEGF
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

NCT01309451
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bevacizumab, dexamethasone intravitreal implant
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

NCT04895293
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
RBM-007 Injectable Solution
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
50 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 8, 2026, 6:24 PM EDT
Withdrawn Phase 2 Interventional

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

NCT02127684
View directory record Official record
Conditions
Persistent Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

NCT02036424
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Raj K. Maturi, MD
Individual
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Oct 8, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

Assessment of Novel Intraocular Injection Guide

NCT02315170
View directory record Official record
Conditions
Retinal Disease
Interventions
intraocular injection guide, standard lid speculum
Device
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 8, 2026, 6:24 PM EDT